To explore the relationship between FSCN1-3 expression levels and the progression of myeloma, we also analyzed FSCN1-3 expression levels of patients from GSE2113 in three different myeloma stages, including MGUS, MM and PCL. Here, FSCN1 is linked to Miyoshi myopathy.